Tink - Glad you like what you see. And though I agree that additional delays in the launch of RapiMeds will not be helpful to the PPS, I respectfully disagree on your timing. I'm a fundamentalist and not a TA expert, nor am I an expert in predicting short-term price movements. But when ScripsAmerica signs its first deal in China, the very low numbers that you are waiting for will be long gone. Moreover, as to your dilution comment, the company has already announced it has the funding it needs to satisfy the first tranche of orders from China. That said, my worst-case scenario at the end of 2014 is 125M O/S, which still sets us up for an EOY price above $0.90 in 2014. And while we are diverted and focused on the RapiMeds story, Scrips will still be growing and expanding its wholesale drug distribution business. Many revenue streams will lead to a stellar 2014 and an even better 2015.
GLTA
News 
Market Data 
Discover 
